vendredi 24 avril 2020

Onco Actu du 24 avril 2020


1. BIOLOGIE



Discovering a Key to the Survival of Dormant Breast Cancer Cells [Dartmouth]










1.1 BIOLOGIE - GÉNOME



Normal human uterus is colonised by clones with cancer-driving mutations that arise early in life, study finds [Sanger Institute]











4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Artificial intelligence can categorize cancer risk of lung nodules [EurekAlert!]











4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



Agilent Receives FDA Approval for PD-L1 Companion Diagnostic on Dako Omnis [Agilent]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Game theory suggests more efficient cancer therapy [Cornell]











5.10 TRAITEMENTS - ESSAIS



New targeted agent produces considerable responses in trial with patients with uterine serous carcinoma [Dana-Farber Cancer Institute]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Pancreatic Cancer Cells Hijack Basic Cell Mechanism to Evade Immunotherapy [NYU Langone]










Research Uncovers Details about How Gut Microbes Influence the Immune System [Memorial Sloan Kettering Cancer Center]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical Trials [NCI]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



GSK presents new data from the GARNET study demonstrating potential of dostarlimab to treat a subset of women with recurrent or advanced endometrial cancer [GSK]











Merck Resubmits Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule [Merck]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



New cancer treatment that tracks and zaps tumors coming to Stanford Medicine [Stanford]











5.2 PHARMA



Lynparza demonstrated overall survival benefit in Phase III PROfound trial for BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer [AstraZeneca]











AstraZeneca's Lynparza shows further promise in prostate cancer study [Reuters]











5.2.3 PHARMA - ÉCONOMIE



Roche culls key phase 3 drug trials, including a cancer med and an autism 'breakthrough' therapy [Fierce Biotech]











5.2.6 PHARMA - BIOTECH



ORIC Pharma Gets $120M in IPO to Advance Drug-Resistant Cancer Therapies [Xconomy]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments [FDA]










FDA grants accelerated approval for Immunomedics' breast cancer therapy [Reuters]











Immunomedics wins long-sought FDA approval for breast cancer drug [Biopharma Dive]











Immunomedics Triple Negative Breast Cancer Drug Wins Early FDA Nod [Xconomy]











FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple Negative Breast Cancer [Immunomedics]











Immunomedics finally wins its blockbuster FDA nod for Trodelvy in triple-negative breast cancer [Fierce Pharma]











5.9 AACR



Bayer to highlight clinical data on Vitrakvi™ (larotrectinib) and research on investigational AhR inhibitor at AACR 2020 Virtual Meeting [Bayer]











AACR 2020 preview – no Tigit, but plenty of novel mechanisms [Evaluate]










6.15 LUTTE CONTRE LES CANCERS - COVID-19



First Report on the Prognosis of COVID-19 Patients with Cancer in the US [ESMO]